LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)

Alexander Stratigos, Aleksandar Sekulić, Ketty Peris, Oliver Bechter, Caroline Dutriaux, Martin Kaatz, Karl D. Lewis, Nicole Basset‐Séguin, Anne Lynn S. Chang, Stéphane Dalle, Almudena Fernández, Lisa Licitra, Caroline Robert, Claas Ulrich, Axel Hauschild, Michael R. Migden, Reinhard Dummer, S. Li, Taylor Bowler, M.G. Fury